Enediyne compounds and methods related thereto

Details Enediyne compounds and methods related thereto Enediyne compounds and methods related thereto

2001-09-25

2003-02-04

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S002000, C546S264000

Reexamination Certificate

active

06514995

ABSTRACT:

FIELD OF THE INVENTION
This invention pertains to tetradentate enediyne ligands and associated metal complexes, and their use in the treatment of cancers and infectious diseases.
BACKGROUND OF THE INVENTION
The potent antitumor activity of the enediyne natural product antibiotics such as calicheamicin, dynemicin, esperamicin, and neocarzinostatin has fostered interest in the development of simple enediynes with low thermal barriers to formation of the lethal 1,4-benzenoid diradical intermediate (see, e.g., Nicolaou, et al.,
Angew. Chem., Int. Ed. Engl
. 1991, 30, 1387; Lee, et al.,
J. Am. Chem. Soc
. 1987, 109, 3466; Konishi, et al.,
J. Am. Chem. Soc
. 1990,112, 3715; Golik, et al.,
J. Am. Chem. Soc
. 1987, 109, 3461; Edo, et al.,
Tet. Lett
., 1985, 26, 331). Such benzenoid diradicals are thought to be capable of cleaving DNA by H-atom abstraction. Benzenoid 1,4-diradicals can be formed via Bergman cyclization of a suitable enediyne.
To this end, carbocyclic enediyne frameworks, and more recently, novel metalloenediyne structures, have been described (see, e.g., commonly assigned published PCT/US00/04915, the entire contents of which are hereby incorporated by reference; Nicolaou, et al.,
J. Am. Chem. Soc
. 1992, 114, 7360; Warner, et al.,
Science
1995, 269, 814; König, et al.,
J. Org. Chem
. 1996, 61, 5258; Basak, et al.,
J. Chem. Soc., Perkin Trans
1 2000, 1955; Coalter, et al.,
J. Am. Chem. Soc
. 2000, 122, 3112; Benites, et al.,
J. Am. Chem. Soc
. 2000, 122, 7208.). The relative disposition of the alkyne termini and the nature of the ring closing are thought to provide steric contributions to the thermal barrier in the Bergman cyclization (Magnus, et al.,
J. Am. Chem. Soc
. 1990, 112, 4986; Snyder, J. P.,
J. Am. Chem. Soc
. 1990, 112, 5367).
The role of chelated transition metals in the Bergman cyclization of certain enediynes has been studied in some laboratories. Notably, the chelation of transition metals has been observed to reduce the thermal barrier in the Bergman cyclization of enediynes. However, heating to about 60° C. is still required for activation of such complexes, which is a relatively high temperature, and limits the usefulness of such compounds from a therapeutic standpoint. This problem can be avoided in some instances by using photoexcitation (e.g., photodynamic therapy (“PDT”)), but such procedures are often limited in terms of therapeutic application, as a light source is required. In addition, long wavelength absorbing species are preferred in biological applications, which raises additional obstacles in terms of developing a therapeutic agent. Accordingly, there is a need for new enediyne ligands and metal complexes thereof, particularly such ligands and complexes that exhibit a lower energy barrier for undergoing the Bergman cyclization, and methods of therapeutically using such ligands and complexes.
The invention provides such tetradentate enediyne ligands and metal complexes thereof, and methods of using them in the treatment of cancer and infectious diseases. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
BRIEF SUMMARY OF THE INVENTION
In one aspect, the invention provides novel tetradentate enediyne ligands that are thermally stable, yet react under photothermal conditions or thermally at about room temperature or slightly higher when complexed with one or more metal ions.
In another aspect, the invention provides a method of prophylactically or therapeutically treating cancer in a mammal (e.g., a human) comprising administering a therapeutically effective amount of a compound of the invention. The compound can be administered alone or as a composition that includes a therapeutically acceptable carrier. In accordance with the invention, the free uncomplexed ligand can be administered to the mammal, such that the ligand contacts a metal in vivo and forms a metal complex in vivo. Alternatively, a metal complex of the invention can be administered to the mammal so as to prophylactically or therapeutically treat cancer and/or an infectious disease in accordance with the invention.
The method of the present invention also includes administering a metal-complexed ligand to a mammal such that the complex contacts and exchanges with a metal in vivo which, in turn, forms a new metal complex in vivo.


REFERENCES:
patent: 5371199 (1994-12-01), Therien et al.
patent: 5986090 (1999-11-01), Therien et al.
patent: 6043237 (2000-03-01), Meadows et al.
Rawat, D.S. et al. : Mg2+ -induced thermal enediyne cyclization at ambient temperature. J. Am. Chem. Soc. vol. 123, pp. 9675-9676, 2001.*
Nicolaou et al. “Molecular Design and Chemical Synthesis of Potent Enediynes,”Chem. Abst., 117, Abstract 233658v and Abstract 233659w, 835 (1992).
U.S. patent application Ser. No. 09/913,924, Zaleski et al., filed Aug. 20, 2001.
Ali et al., “Metal Complexes as Photo- and Radiosensitizers,”Chem. Rev., 99, 2379-2450 (1999).
Basak et al., “The Synthesis and Reactivity of Novel Azetidinyl Enediynes,”Chem. Commun., 749-750 (1996).
Bergman, “Reactive 1,4-Dehydroaromatics,”Accounts of Chemical Research, 6, 25-31 (1973).
Bonadies et al., “Vanadium Phenolates as Models for Vanadium in Biological Systems. 1. Synthesis, Spectroscopy, and Electrochemistry of Vanadium Complexes of Ethylenebis [(o-hydroxyphenyl)glycine] and its Derivatives,”J. Am. Chem. Soc., 108, 4088-4095 (1986).
Bonnett, “Photosensitizers of the Porphyrin and Phtalocyanine Series for Photodynamic Therapy,”Chem. Soc. Reviews, 24, 19-33 (1995).
Boyle et al., “Structure and Biodistribution Relationships of Photodynamic Sensitizers,”Photochemistry and Photobiology, 64(3), 469-485 (1996).
Branca et al., “Formation and Structure of the Tris(catecholato)vanadate(IV) Complex in Aqueous Solution,”Inorg. Chem., 29, 1586-1589 (1990).
Chapman et al., “9,10-Dehydroanthracene. A Derivative of 1,4-Dehydrobenzene,”J. Am. Chem. Soc., 98(18), 5703-5705 (1976).
Christner et al., “Unmasking the Chemistry of DNA Cleavage by the Esperamicins: Modulation of 4′-Hydrogen Abstraction and Bistranded Damage by the Fucose- Anthranilate Moiety,”J. Am. Chem. Soc., 114, 8763-8767 (1992).
Churcher et al., “Synthesis of the Enediyne Aglycon (±)-Calicheamicinone,”J. Am. Chem. Soc., 120, 3518-3519 (1998).
Cummings et al., “Luminescent Platinum (II) Complexes of Quinoxaline-2,3-dithiolate,”Inorg. Chem., 34, 2007-2014 (1995).
Cummings et al., “Tuning the Excited-State Properties of Platinum (II) Diimine Dithiolate Complexes,”J. Am. Chem. Soc., 118, 1949-1960 (1996).
Dai et al., “Synthesis and DNA Clavage Study of a 10-Membered Ring Enediyne Formed via Allylic Rearrangement,”J. Org. Chem., 64, 682-683 (1999).
Evenzahav et al., “Photochemical Rearragement of Endiynes: Is a “Photo-Bergman” Cyclization a Possibility?”J. Am. Chem. Soc., 120, 1835-1841 (1998).
Funk et al., “Photochemical Cycloaromatization Reactions of ortho-Dialkynylarenes: A New Class of DNA Photocleaving Agents,”J. Am. Chem. Soc., 118, 3291-3292 (1996).
Golik et al., “Esperamicins, a Novel Class of Potent Antitumor Antibiotics. 2. Structure of Esperamicin X,”J. Am. Chem. Soc., 109, 3461-3462 (1987).
Golik et al., “Esperamicns, a Novel Class of Potent Antitumor Antibiotics. 3. Structures of Esperamicins A1, A2, and A1b,”J. Am. Chem. Soc., 109, 3462-3464 (1987).
Hangeland et al., “Specific Abstraction of the 5′(S)- and 4′-Deoxyribosyl Hydrogen Atoms from DNA by Calicheamicin &ggr;1,”J. Am. Chem. Soc., 114, 9200-9202 (1992).
Holmes et al., “Models for the Binding Site in Bromoperoxidase: Mononuclear Vanadium (V) Phenolate Complexes of the Hydridotris(3,5-dimethylpyrazolyl)borate Ligand,”Inorg. Chem., 30, 1231-1235 (1991).
Kaneko et al., “Photochemical Cycloaromatization of Non-Benzenoid Enediynes,” Angew. Chem. Int. Ed., 38 (9), 1267-1268 (1999).
Kim et al., “Rapid Bergman Cyclization of 1,2-Diethynylheteroarenes,”J. Org. Chem., 63, 8229-8234 (1998).
Konig et al., “Activation of Macrocyclic Biaryl-Enediynes by Metal Ion Coordi

Affiliated with

Also associated with

Rating

Enediyne compounds and methods related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enediyne compounds and methods related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enediyne compounds and methods related thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3178219